What happens in the joint during the first 72 hours

Soreness after a ChondroFiller injection is expected — and it is worth understanding why, so the days following your outpatient appointment are not needlessly worrying.

Most patients notice mild localised aching, swelling, and stiffness within the first 24–72 hours. This is the joint responding to the introduction of the collagen scaffold, not a sign that something has gone wrong. The response typically settles on its own without any specific treatment.

One reassurance worth holding onto: by the time you leave the clinic, the structural work is already done. The collagen solution gels into a firm scaffold within 3–5 minutes of injection at body temperature, bonding with the body's natural fibrin to anchor within the cartilage defect. The biological process of recruiting your own repair cells then begins — but the physical scaffold is established from the outset.

For the first 48–72 hours, standard RICE measures apply: rest the treated joint, apply an ice pack intermittently, and keep the limb elevated where possible to limit swelling. Avoid driving and prolonged walking on the day of the injection. Most patients with desk-based roles can return to work within 24–48 hours.

Why recovery takes months, not days — the biology

The recovery timeline is not arbitrary caution — it reflects the pace at which biology actually works.

Once the scaffold is anchored in the defect, it begins to act as a temporary framework for a process called acellular matrix-induced chondrogenesis. Rather than delivering cells itself, ChondroFiller recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, which migrate into the scaffold and gradually differentiate into cartilage-forming cells. The scaffold supports the body's own repair processes; it does not independently regrow tissue.

A 2025 ex vivo study provided a measurable window into this early biology: ChondroFiller scaffolds showed a 2.4-fold increase in DNA content by day 14, confirming that meaningful progenitor cell migration begins within the first fortnight. From that point, maturation is progressive — cells continue differentiating over approximately 12 months, and the collagen scaffold itself is progressively replaced by the patient's own tissue over one to two years.

This biological arc explains why the recovery milestones described in the sections below are spaced weeks and months apart. Premature mechanical loading risks disturbing the scaffold before it has been adequately colonised; suppressing the early inflammatory response with NSAIDs may blunt the very signalling that draws progenitor cells in. The phased approach works with this timeline, not against it.

What to avoid and the reason behind each restriction

A 2024 biomechanical in-vitro study that tested ChondroFiller under cyclic loading found initial mechanical instability in the scaffold before adequate cell colonisation has occurred — meaning the load restrictions in weeks 1–6 rest on direct experimental evidence, not precaution alone. High-impact activity, heavy lifting, twisting movements, and prolonged standing all place repetitive stress on a structure that is not yet mechanically mature. The aim of curtailing these for the first four to six weeks is to protect the scaffold while cell migration is under way.

The guidance on pain relief follows similar logic. Many people instinctively reach for ibuprofen after a procedure, but the early inflammatory environment around the scaffold is part of the recruitment signal that draws progenitor cells into the defect — not merely an inconvenience to be suppressed. Non-steroidal anti-inflammatory drugs can blunt that signal, potentially impairing the chondrogenesis the treatment depends on. Paracetamol provides adequate pain control without this risk; if NSAIDs are genuinely needed — for instance, in patients already taking them for another condition — the treating clinician should be consulted before continuing their use.

Where possible, reducing alcohol intake and avoiding smoking in the weeks following the injection is also advisable. Both can compromise local vascular supply and the tissue environment that newly migrating cells require to establish themselves.

Finally, weight-bearing protocols for large joints such as the knee and hip are not uniform. The treating clinician will factor in defect size, joint location, and body weight before advising on the pace of loading. Self-escalating activity ahead of that guidance risks disrupting biological progress that will not yet be visible on any scan.

The four recovery phases and what each one involves

Recovery from a ChondroFiller injection follows a consistent four-phase arc, each unlocking new activity as the scaffold matures beneath it.

Phase 1 — Protection (weeks 0–6)

The priority in this first period is safeguarding the scaffold while progenitor cell migration is under way. Joint loading is limited, range-of-motion exercises are kept controlled, and high-impact movement is off the table entirely. Pain management centres on paracetamol. The scaffold is present and anchoring; the biological work is just beginning.

Phase 2 — Strengthening (weeks 6–12)

At six weeks, the window opens for more purposeful rehabilitation — but under the direction of a treating physiotherapist, not self-guided. Stationary cycling and swimming are typically introduced at this point, offering cardiovascular conditioning and joint movement without the repetitive impact that could still disturb the maturing scaffold. Gait normalisation is a central goal for lower-limb injections. Walking restrictions are generally lifted during this phase.

Phase 3 — Functional loading (months 2–6)

Progressive loading is introduced incrementally. Light jogging and sport-specific movement drills become appropriate for most patients, again under physiotherapy supervision. The scaffolded defect is now more structurally sound, and loading supports rather than endangers the repair environment.

Phase 4 — Return to sport (months 6–12+)

High-impact sport and competitive activity require specialist sign-off — not simply the passage of time. Real-world outcome data reflects this arc: in a published knee series of 17 patients, Lysholm and IKDC scores improved significantly at three and six months, with scores plateauing as activity normalised between six and twelve months — consistent with the repair tissue reaching functional maturity in that window.

Hip data offer a longer view: in a cohort of 26 patients followed for 12–60 months, 17 of 21 available at three to five years reported good or excellent results. Patients with advanced pre-existing osteoarthritis fared materially worse — a realistic context to hold alongside the positive findings.

How recovery differs for small joints versus the knee and hip

Not every ChondroFiller patient faces a year-long recovery — and for those who have had a small joint injection, the difference is substantial.

For the wrist and thumb base, the protected rest period is typically just one to two weeks before activity is gradually resumed. A 2023 study by Coarin and colleagues in thumb base osteoarthritis found statistically significant improvements in both NRS pain scores and DASH (Disability of the Arm, Shoulder and Hand) scores at just 30 days post-injection — a timeline that reflects how differently a non-weight-bearing joint heals compared with the knee or hip.

The 6–12-month arc outlined in the preceding section is most relevant to large weight-bearing joints, where repetitive compressive loads are far more demanding on the maturing scaffold and the defect tends to be more structurally significant. An ankle, knee, or hip must eventually bear many times body weight with each step; a thumb does not.

For the lower-limb joints specifically, the precise pace of weight progression — including whether crutches are required and for how long — is not standardised. Clinicians factor in defect size, joint anatomy, and individual body weight before advising on loading. Following that personalised guidance, rather than a generic schedule, is the most reliable way to avoid setting back the repair process.

Signs to watch for and when to contact your clinic

The vast majority of patients pass through the first weeks without complication. Mild aching, localised swelling, and slight stiffness in the first 72 hours are part of the expected joint response — they settle without intervention and do not require contacting the clinic.

A smaller set of symptoms falls outside that expected range and should prompt early contact with your treating clinician:

• Severe or worsening pain that has not begun to ease by 72 hours post-injection
• Spreading redness around the joint, rather than the localised tenderness typical in the first day or two
• Fever or any other sign of systemic infection

These presentations are uncommon after an ultrasound-guided outpatient injection, but early assessment matters when they do occur.

Follow-up beyond the immediate recovery period is clinician-led. Outcome review — typically incorporating MOCART MRI scoring to assess the repair site — is usually arranged at six and twelve months, once the developing tissue has matured sufficiently for meaningful evaluation. For any concerns or change in symptoms between appointments, contacting your clinician directly is always preferable to self-management; for those yet to begin a treatment pathway, assessments are available through londoncartilage.com.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z